RU2470652C2 - Пробиотики в пред- и/или послеоперационный период - Google Patents
Пробиотики в пред- и/или послеоперационный период Download PDFInfo
- Publication number
- RU2470652C2 RU2470652C2 RU2009147036/15A RU2009147036A RU2470652C2 RU 2470652 C2 RU2470652 C2 RU 2470652C2 RU 2009147036/15 A RU2009147036/15 A RU 2009147036/15A RU 2009147036 A RU2009147036 A RU 2009147036A RU 2470652 C2 RU2470652 C2 RU 2470652C2
- Authority
- RU
- Russia
- Prior art keywords
- composition
- use according
- probiotics
- nutritional composition
- source
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 64
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 64
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 21
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 98
- 239000003814 drug Substances 0.000 claims abstract description 36
- 241001468157 Lactobacillus johnsonii Species 0.000 claims abstract description 13
- 206010070545 Bacterial translocation Diseases 0.000 claims abstract description 4
- 230000007375 bacterial translocation Effects 0.000 claims abstract description 4
- 206010056519 Abdominal infection Diseases 0.000 claims abstract description 3
- 206010058674 Pelvic Infection Diseases 0.000 claims abstract description 3
- 230000003187 abdominal effect Effects 0.000 claims abstract description 3
- 238000009825 accumulation Methods 0.000 claims abstract description 3
- 230000003872 anastomosis Effects 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract 2
- 235000016709 nutrition Nutrition 0.000 claims description 55
- 235000018102 proteins Nutrition 0.000 claims description 34
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 34
- 229940079593 drug Drugs 0.000 claims description 33
- 150000002632 lipids Chemical class 0.000 claims description 22
- 241000894006 Bacteria Species 0.000 claims description 21
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 12
- 235000014633 carbohydrates Nutrition 0.000 claims description 12
- 235000013406 prebiotics Nutrition 0.000 claims description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 5
- 229930003268 Vitamin C Natural products 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 5
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 5
- 235000019154 vitamin C Nutrition 0.000 claims description 5
- 239000011718 vitamin C Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011785 micronutrient Substances 0.000 claims description 3
- 235000013369 micronutrients Nutrition 0.000 claims description 3
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 3
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 210000004197 pelvis Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 7
- 238000012321 colectomy Methods 0.000 abstract description 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 abstract description 2
- 230000000112 colonic effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 description 31
- 239000000835 fiber Substances 0.000 description 21
- 108010046377 Whey Proteins Proteins 0.000 description 14
- 102000007544 Whey Proteins Human genes 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 13
- 235000021119 whey protein Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 9
- 206010012735 Diarrhoea Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 241000736262 Microbiota Species 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 239000011701 zinc Substances 0.000 description 7
- 229910052725 zinc Inorganic materials 0.000 description 7
- 241000186000 Bifidobacterium Species 0.000 description 6
- 241000186660 Lactobacillus Species 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 5
- 235000013734 beta-carotene Nutrition 0.000 description 5
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 5
- 239000011648 beta-carotene Substances 0.000 description 5
- 229960002747 betacarotene Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 229940057917 medium chain triglycerides Drugs 0.000 description 5
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 5
- 229920001202 Inulin Polymers 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 4
- 229940029339 inulin Drugs 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 150000004671 saturated fatty acids Chemical class 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000193163 Clostridioides difficile Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 230000015323 positive regulation of phagocytosis Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 235000003441 saturated fatty acids Nutrition 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- -1 xyloligosaccharides Polymers 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 235000019487 Hazelnut oil Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 206010039921 Selenium deficiency Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000037063 Thinness Diseases 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- YGCFIWIQZPHFLU-UHFFFAOYSA-N acesulfame Chemical compound CC1=CC(=O)NS(=O)(=O)O1 YGCFIWIQZPHFLU-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010878 colorectal surgery Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000010468 hazelnut oil Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940059406 lactobacillus rhamnosus gg Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 206010048828 underweight Diseases 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- 229940045999 vitamin b 12 Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07108492.5A EP1992351B1 (en) | 2007-05-18 | 2007-05-18 | Lactobacillus johnsonii for prevention of postsurgical infection |
| EP07108492.5 | 2007-05-18 | ||
| PCT/EP2008/055898 WO2008141989A1 (en) | 2007-05-18 | 2008-05-14 | Probiotics in a pre- and/or post surgical environment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009147036A RU2009147036A (ru) | 2011-06-27 |
| RU2470652C2 true RU2470652C2 (ru) | 2012-12-27 |
Family
ID=38476047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009147036/15A RU2470652C2 (ru) | 2007-05-18 | 2008-05-14 | Пробиотики в пред- и/или послеоперационный период |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8529887B2 (https=) |
| EP (2) | EP1992351B1 (https=) |
| JP (2) | JP5497634B2 (https=) |
| CN (2) | CN101678054A (https=) |
| AU (1) | AU2008253040B2 (https=) |
| BR (1) | BRPI0811180A2 (https=) |
| CA (1) | CA2686976C (https=) |
| CL (1) | CL2008001446A1 (https=) |
| DK (1) | DK1992351T3 (https=) |
| ES (1) | ES2578261T3 (https=) |
| MX (1) | MX2009012255A (https=) |
| RU (1) | RU2470652C2 (https=) |
| TW (1) | TW200902040A (https=) |
| WO (1) | WO2008141989A1 (https=) |
| ZA (1) | ZA200909002B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2565444C2 (ru) * | 2013-11-28 | 2015-10-20 | Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук | Способ профилактики инфекционно-воспалительных осложнений у женщин с субмукозной миомой матки после гистерорезектоскопии |
| RU2628063C1 (ru) * | 2016-09-22 | 2017-08-14 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогнозирования транслокации E.coli из кишечника при некультивируемом типе инфекционного процесса в эксперименте на кроликах |
| RU2642327C1 (ru) * | 2016-10-06 | 2018-01-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогноза развития патогенетического процесса по некультивируемому или культивируемому типу в эксперименте |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2578261T3 (es) * | 2007-05-18 | 2016-07-22 | Nestec S.A. | Lactobacillus johnsonii para prevenir infecciones postoperatorias |
| CA2724554A1 (en) * | 2008-05-15 | 2009-11-19 | Youdocs, Llc | Methods and systems for improving human health using targeted probiotics |
| WO2010096550A2 (en) * | 2009-02-18 | 2010-08-26 | University Of Florida Research Foundation, Inc. | Lactobacillus supplement for alleviating type 1 diabetes |
| WO2010096564A2 (en) * | 2009-02-19 | 2010-08-26 | Probiohealth Llc | Dietary supplements containing polyunsaturated omega-3 fatty acids and probiotic bacteria with potential gastrointestinal and dermatological benefits |
| EP2413849B1 (en) | 2009-04-03 | 2014-07-02 | Metamodix, Inc. | Modular gastrointestinal prostheses |
| US9173760B2 (en) | 2009-04-03 | 2015-11-03 | Metamodix, Inc. | Delivery devices and methods for gastrointestinal implants |
| US9278019B2 (en) | 2009-04-03 | 2016-03-08 | Metamodix, Inc | Anchors and methods for intestinal bypass sleeves |
| US8784798B2 (en) * | 2009-05-11 | 2014-07-22 | Nestec S.A. | Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders |
| EP2251020A1 (en) * | 2009-05-11 | 2010-11-17 | Nestec S.A. | Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles |
| EP2251022A1 (en) * | 2009-05-11 | 2010-11-17 | Nestec S.A. | Non-replicating micro-organisms and their immune boosting effect |
| EP2459203B1 (en) * | 2009-07-30 | 2018-10-31 | DuPont Nutrition Biosciences ApS | Lactic acid bacteria and bifidobacteria for treating endotoxemia |
| EP2691089A1 (en) * | 2011-03-31 | 2014-02-05 | Nestec S.A. | Nutritional compositions for increasing arginine levels and methods of using same |
| KR101869498B1 (ko) * | 2011-04-08 | 2018-06-22 | 시에이치알. 한센 에이/에스 | 시너지적 항균 효과 |
| EP2717890B1 (de) * | 2011-06-08 | 2016-08-10 | OrganoBalance GmbH | Sprühgetrocknete lactobacillus stämme / zellen und deren verwendung gegen helicobacter pylori |
| CN102835657B (zh) * | 2011-06-20 | 2014-08-20 | 丰华生物科技股份有限公司 | 用以抑制发炎反应及抗阴道炎的含乳酸菌食品组合物及医药组合物 |
| IN2014DN07752A (https=) | 2012-02-29 | 2015-05-15 | Ethicon Endo Surgery Inc | |
| JP6203816B2 (ja) | 2012-03-29 | 2017-09-27 | セラバイオーム，エルエルシー | 回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤 |
| WO2013153070A1 (en) | 2012-04-09 | 2013-10-17 | Chr. Hansen A/S | Bioprotection using lactobacillus paracasei strains |
| CN104284975B (zh) * | 2012-04-09 | 2016-08-24 | 科.汉森有限公司 | 应用鼠李糖乳杆菌菌株的生物保护 |
| EP2945566A4 (en) | 2013-01-15 | 2016-10-26 | Metamodix Inc | SYSTEM AND METHOD FOR MODIFYING MICROBIAL INTESTINAL FLORA |
| AU2014239883B2 (en) | 2013-03-14 | 2019-01-17 | Therabiome, Llc | Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents |
| KR101445243B1 (ko) * | 2014-03-28 | 2014-09-29 | 서울대학교산학협력단 | 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단 |
| SG10201903823QA (en) | 2014-10-31 | 2019-05-30 | Whole Biome Inc | Methods and compositions relating to microbial treatment and diagnosis of disorders |
| US9622897B1 (en) | 2016-03-03 | 2017-04-18 | Metamodix, Inc. | Pyloric anchors and methods for intestinal bypass sleeves |
| WO2017201424A1 (en) | 2016-05-19 | 2017-11-23 | Metamodix, Inc. | Pyloric anchor retrieval tools and methods |
| WO2018112194A1 (en) | 2016-12-15 | 2018-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for modulating growth of a genetically modified gut bacterial cell |
| CN111372596A (zh) | 2017-08-30 | 2020-07-03 | 潘德勒姆治疗公司 | 用于治疗微生物组相关病症的方法和组合物 |
| CA3106315A1 (en) | 2018-07-19 | 2020-01-23 | Pendulum Therapeutics, Inc. | Methods and compositions for microbial engraftment |
| TWI718402B (zh) * | 2018-08-16 | 2021-02-11 | 葡萄王生技股份有限公司 | 副乾酪乳酸桿菌gks6之活性物質、含其之組合物及其促進長壽之用途 |
| TWI784194B (zh) * | 2019-09-04 | 2022-11-21 | 台達電子工業股份有限公司 | 抑制具萬古黴素抗藥性腸球菌之益生菌組合與其用途 |
| CN112438995A (zh) | 2019-09-04 | 2021-03-05 | 台达电子工业股份有限公司 | 抑制具万古霉素抗药性肠球菌的益生菌及其组合与其用途 |
| US20220193156A1 (en) * | 2020-12-23 | 2022-06-23 | Thi Tuyet Mai Ta | Preoperative compositions and methods of preparation thereof |
| US12377123B2 (en) * | 2020-12-23 | 2025-08-05 | Preoperative Nutrition | Preoperative compositions and methods of preparation thereof |
| CN113559131A (zh) * | 2021-07-23 | 2021-10-29 | 科为博(江苏)生物科技研究院有限公司 | 一种用于改善肠胃的益生菌粉 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0861905A2 (en) * | 1997-02-27 | 1998-09-02 | Proge Farm S.r.l. | Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system |
| WO1999007393A1 (en) * | 1997-08-05 | 1999-02-18 | Rodica Teodorescu | Pharmaceutical product comprising bacterial strains for the colon therapy |
| WO2006046871A2 (en) * | 2004-10-29 | 2006-05-04 | N.V. Nutricia | Peri-operative composition comprising lactobacillus rhamnosus |
| RU2293568C1 (ru) * | 2006-01-10 | 2007-02-20 | Федеральное государственное учреждение Российский центр функциональной хирургической гастроэнтерологии Федерального агентства по здравоохранению и социальному развитию (ФГУ "РЦФХГ Росздрава") | Способ периоперационной коррекции дисбиоза толстой кишки у больных колоректальным раком |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0768375B2 (fr) * | 1992-07-06 | 2002-06-12 | Societe Des Produits Nestle S.A. | Bactérie lactique |
| EP0577903B1 (fr) * | 1992-07-06 | 1997-12-17 | Societe Des Produits Nestle S.A. | Agent antigastrite |
| DE69707413T3 (de) * | 1997-01-09 | 2009-07-02 | Société des Produits Nestlé S.A. | Probiotik enthaltendes Getreideprodukt |
| ES2168785T5 (es) | 1997-07-05 | 2009-04-16 | Societe Des Produits Nestle S.A. | Absorcion de minerales por las celulas intestinales. |
| MXPA02009342A (es) * | 2000-03-24 | 2003-09-22 | Nestle Sa | Uso de bacterias de acido lactico para el tratamiento de la peritonitis. |
| AU5625001A (en) * | 2000-04-18 | 2001-10-30 | Societe Des Produits Nestle S.A. | Nutritional modules |
| GB0027761D0 (en) * | 2000-11-14 | 2000-12-27 | Nestle Sa | Nutritional composition for an immune condition |
| US20030092163A1 (en) | 2001-07-26 | 2003-05-15 | Collins John Kevin | Probiotic bifidobacterium strains |
| SI1565547T2 (sl) * | 2002-06-28 | 2013-02-28 | Biosearch S.A. | Probiotiäśni sevi, postopek za izbiranje le-teh, njihovi sestavki in njihova uporaba |
| PL1638416T3 (pl) * | 2003-06-23 | 2013-09-30 | Nestec Sa | Zastosowanie żywnościowego preparatu do optymalizowania działania bariery jelitowej |
| KR20060109452A (ko) * | 2003-10-02 | 2006-10-20 | 더 바이오 밸런스 코포레이션 | 건조 바이오치료 조성물, 용도, 그 투여 장치 및 투여 방법 |
| US7862808B2 (en) * | 2004-07-01 | 2011-01-04 | Mead Johnson Nutrition Company | Method for preventing or treating respiratory infections and acute otitis media in infants using Lactobacillus rhamnosus LGG and Bifidobacterium lactis Bb-12 |
| US7595079B2 (en) * | 2005-07-08 | 2009-09-29 | Bomac Vets Plus, Inc. | Nutritional conjunctive support therapy for recovery in animals following stress or illness |
| ES2578261T3 (es) * | 2007-05-18 | 2016-07-22 | Nestec S.A. | Lactobacillus johnsonii para prevenir infecciones postoperatorias |
-
2007
- 2007-05-18 ES ES07108492.5T patent/ES2578261T3/es active Active
- 2007-05-18 EP EP07108492.5A patent/EP1992351B1/en active Active
- 2007-05-18 DK DK07108492.5T patent/DK1992351T3/en active
-
2008
- 2008-05-14 CA CA2686976A patent/CA2686976C/en active Active
- 2008-05-14 JP JP2010507914A patent/JP5497634B2/ja active Active
- 2008-05-14 WO PCT/EP2008/055898 patent/WO2008141989A1/en not_active Ceased
- 2008-05-14 CN CN200880016429A patent/CN101678054A/zh active Pending
- 2008-05-14 BR BRPI0811180-4A2A patent/BRPI0811180A2/pt not_active Application Discontinuation
- 2008-05-14 AU AU2008253040A patent/AU2008253040B2/en active Active
- 2008-05-14 CN CN201310631541.XA patent/CN103623010A/zh active Pending
- 2008-05-14 MX MX2009012255A patent/MX2009012255A/es unknown
- 2008-05-14 RU RU2009147036/15A patent/RU2470652C2/ru not_active IP Right Cessation
- 2008-05-14 EP EP08750285A patent/EP2146729A1/en not_active Withdrawn
- 2008-05-14 US US12/598,905 patent/US8529887B2/en active Active
- 2008-05-16 TW TW097118169A patent/TW200902040A/zh unknown
- 2008-05-16 CL CL2008001446A patent/CL2008001446A1/es unknown
-
2009
- 2009-12-17 ZA ZA2009/09002A patent/ZA200909002B/en unknown
-
2013
- 2013-05-22 JP JP2013108350A patent/JP6285108B2/ja active Active
- 2013-08-23 US US13/974,693 patent/US9616094B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0861905A2 (en) * | 1997-02-27 | 1998-09-02 | Proge Farm S.r.l. | Novel lactobacilli strains useful in the treatment of disorders of the gastrointestinal system |
| WO1999007393A1 (en) * | 1997-08-05 | 1999-02-18 | Rodica Teodorescu | Pharmaceutical product comprising bacterial strains for the colon therapy |
| WO2006046871A2 (en) * | 2004-10-29 | 2006-05-04 | N.V. Nutricia | Peri-operative composition comprising lactobacillus rhamnosus |
| RU2293568C1 (ru) * | 2006-01-10 | 2007-02-20 | Федеральное государственное учреждение Российский центр функциональной хирургической гастроэнтерологии Федерального агентства по здравоохранению и социальному развитию (ФГУ "РЦФХГ Росздрава") | Способ периоперационной коррекции дисбиоза толстой кишки у больных колоректальным раком |
Non-Patent Citations (12)
| Title |
|---|
| Besselink MG et al. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial [ISRCTN38327949]. BMC Surg. 2004 Sep 29; 4:12. [он-лайн] [най-дено 2011-01-13] Найдено из базы данных PubMed PubMed ID 15456517CiteNPL. * |
| Chourasia MK et al. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003 Jan-Apr; 6 (1):33-66. Реферат [он-лайн] [найдено 2011-06-28] Найдено из базы данных PubMed PMID: 12753729. МИХАЙЛОВ И.Б. Настольная книга врача по клинической фармакологии. - СПб.: Фолиант, 2001, с.258-260. * |
| Chourasia MK et al. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci. 2003 Jan-Apr; 6 (1):33-66. Реферат [он-лайн] [найдено 2011-06-28] Найдено из базы данных PubMed PubMed ID 12753729. * |
| Goossens DA et al. The effect of a probiotic drink with Lactobacillus planta-rum 299v on the bacterial composition in faeces and mucosal biopsies of rec-tum and ascending colon. Aliment Pharmacol Ther. 2006 Jan 15; 23 (2):255-63. Реферат [он-лайн] [найдено 2011-06-28] Найдено из базы данных PubMed PMID: 16393305. * |
| БОЛЬШАЯ ЭНЦИКЛОПЕДИЯ. - М.: ТЕРРА, 2006, т.21, с.506 - статья «Кишечник», т.33, с.202 - статья «Ободочная кишка». * |
| БОЛЬШАЯ ЭНЦИКЛОПЕДИЯ. - М.: ТЕРРА, 2006, т.21, с.506 - статья «Кишечник», т.33, с.202 - статья «Ободочная кишка». БУРБЕЛЛО А.Т. и др. Современные лекарственные средства. - СПб.: Нева, 2004, с.201-202. ШАНИН В.Ю. Клиническая патофизиология. - СПб.: Специальная литература, 1998, с.412-417. Goossens DA et al. The effect of a probiotic drink with Lactobacillus planta-rum 299v on the bacterial composition in faeces and mucosal biopsies of rec-tum and ascending colon. Aliment Pharmacol Ther. 2006 Jan 15; 23 (2):255-63. Реферат [он-лайн] [найдено 2011-06-28] Найдено из базы данных PubMed PMID: 16393305. * |
| БУРБЕЛЛО А.Т. и др. Современные лекарственные средства. - СПб.: Нева, 2004, с.201-202. * |
| Григорьев А.В. и др. Опыт применения бифидумбактерина-форте в детской хирургической практике. - Новые лекарственные средства. - М., 1996, вып.1 [он-лайн] [найдено 2010-07-02] Найдено из Интернет http://www.partner.com.ru/arts/artl27/144.htm. * |
| ИНСТРУКЦИЯ по применению биологически активной добавки к пище «РЕКИЦЕН-РД». Регистрационное удостоверение МЗ РФ 004508. Р.643. 08.2002. * |
| ИНСТРУКЦИЯ по применению биологически активной добавки к пище «РЕКИЦЕН-РД». Регистрационное удостоверение МЗ РФ №004508. Р.643. 08.2002. Григорьев А.В. и др. Опыт применения бифидумбактерина-форте в детской хирургической практике. - Новые лекарственные средства. - М., 1996, вып.1 [он-лайн] [найдено 2010-07-02] Найдено из Интернет http://www.partner.com.ru/arts/artl27/144.htm. Besselink MG et al. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial [ISRCTN38327949]. BMC Surg. 2004 Sep 29; 4:12. [он-лайн] [най-дено 2011-01-13] Найдено из базы данных PubMed PMID: 15456517. * |
| МИХАЙЛОВ И.Б. Настольная книга врача по клинической фармакологии. - СПб.: Фолиант, 2001, с.258-260. * |
| ШАНИН В.Ю. Клиническая патофизиология. - СПб.: Специальная литература, 1998, с.412-417. * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2565444C2 (ru) * | 2013-11-28 | 2015-10-20 | Федеральное государственное бюджетное учреждение науки Институт клеточного и внутриклеточного симбиоза Уральского отделения Российской академии наук | Способ профилактики инфекционно-воспалительных осложнений у женщин с субмукозной миомой матки после гистерорезектоскопии |
| RU2628063C1 (ru) * | 2016-09-22 | 2017-08-14 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогнозирования транслокации E.coli из кишечника при некультивируемом типе инфекционного процесса в эксперименте на кроликах |
| RU2642327C1 (ru) * | 2016-10-06 | 2018-01-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Тюменский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Тюменский ГМУ Минздрава России) | Способ прогноза развития патогенетического процесса по некультивируемому или культивируемому типу в эксперименте |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103623010A (zh) | 2014-03-12 |
| BRPI0811180A2 (pt) | 2014-10-21 |
| MX2009012255A (es) | 2009-11-25 |
| TW200902040A (en) | 2009-01-16 |
| US20100135971A1 (en) | 2010-06-03 |
| DK1992351T3 (en) | 2016-06-06 |
| ES2578261T3 (es) | 2016-07-22 |
| JP5497634B2 (ja) | 2014-05-21 |
| CA2686976C (en) | 2015-02-17 |
| EP2146729A1 (en) | 2010-01-27 |
| EP1992351A1 (en) | 2008-11-19 |
| RU2009147036A (ru) | 2011-06-27 |
| WO2008141989A1 (en) | 2008-11-27 |
| CL2008001446A1 (es) | 2009-10-02 |
| US8529887B2 (en) | 2013-09-10 |
| AU2008253040B2 (en) | 2014-06-12 |
| JP6285108B2 (ja) | 2018-02-28 |
| AU2008253040A1 (en) | 2008-11-27 |
| CA2686976A1 (en) | 2008-11-27 |
| US20130344044A1 (en) | 2013-12-26 |
| EP1992351B1 (en) | 2016-05-11 |
| US9616094B2 (en) | 2017-04-11 |
| CN101678054A (zh) | 2010-03-24 |
| JP2013216658A (ja) | 2013-10-24 |
| JP2010527343A (ja) | 2010-08-12 |
| ZA200909002B (en) | 2011-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2470652C2 (ru) | Пробиотики в пред- и/или послеоперационный период | |
| TWI494114B (zh) | 鼠李醣乳酸桿菌gg(lgg)於治療、預防或減輕全身性發炎之用途 | |
| JP6027491B2 (ja) | 腎臓機能を増大させるための組成物および方法 | |
| KR100497770B1 (ko) | 스트렙토코커스 써머필러스와 비피도박테리움 롱검을 포함하는 경장(經腸)용 식이조성물 | |
| EP0904784A1 (en) | Probiotic nutritional preparation | |
| CN1946412B (zh) | 炎性肠病的预防和/或治疗剂 | |
| KR20070122480A (ko) | 조제유-수유 유아에서의 전신성 염증의 치료, 예방 또는감소를 위한 락토바실루스 람노수스 ｇｇ의 용도 | |
| WO2025099321A1 (en) | Compositions comprising human milk oligosaccharides and inactivated cells of a microorganism | |
| HK1141729B (en) | Method for treating or preventing systemic inflammation | |
| HK1104455A (en) | Preventive and/or remedy for inflammatory bowel diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150515 |